Research Antibodies Market

Research Antibodies Market Overview

The Global Research Antibodies Market was valued at USD 3.32 billion in 2024 and is projected to reach USD 12.32 billion by 2033, growing at a CAGR of 10.25% from 2024 to 2033.

The immune system produces proteins called antibodies in reaction to the introduction of a foreign material called an antigen. There are many applications for antibodies in fundamental science, medicine, and diagnostics. The immune system uses antibodies as a first line of defense against diseases, allergies, and infections. These proteins are produced by the body spontaneously. Occasionally, monoclonal antibodies created in laboratories are used to treat conditions including rheumatoid arthritis, cancer, heart disease, and others. Increased funding for proteomics research and drug discovery, rising rates of cancer and other chronic diseases with rising healthcare costs, population growth, urbanization, and industrialization, as well as various government agencies supporting this R&D growth by funding it and easing regulatory burdens, are the main factors driving the market for research antibodies.

Antibodies are being used by researchers to find protein biomarkers for early illness detection, which might strengthen immune systems and lessen the need for booster shots. Innovation depends on cooperation between academic institutions and corporate R&D departments, and this cooperation has grown as a result of technical advancement and economic volatility. Research-specific antibodies and reagents are being promoted by market participants.

Research Antibodies Market Segment Analysis:

Because of their many uses in research and development as well as laboratory operations, primary antibodies—which accounted for 74.46% of revenue in 2023—are predicted to rise quickly. From 2024 to 2030, secondary antibodies—which are easier and less expensive to produce—are anticipated to expand at a substantial CAGR. Secondary antibodies conjugated with fluorescent dyes are available from Thermo Fisher Scientific for a range of uses.

Due to a dramatic rise in the number of cancer research projects requiring high specificity antibodies, the monoclonal antibodies category had the largest market share in 2023. Monoclonal antibodies are used in the detection and creation of novel treatments for a variety of cancer types because they effectively attach to or inhibit antigens on cancer cells. It is anticipated that this element will increase the segment's growth possibilities in the near future. Since these antibody structures are crucial for the research elements focused on antigen purification and histopathological tissue inspection, polyclonal antibodies are anticipated to expand at a profitable compound annual growth rate (CAGR) during the forecast period. Additionally, the market is growing because polyclonal antibodies provide advantages such durability, easy storage, high affinity, and superior compatibility with western blotting and ELISA technologies.

Because the technique is so widely available and used, the Western blotting category held the greatest market share in 2023. Furthermore, the western blotting approach is usually used over other technologies for applications involving the identification of significant protein entities because of its higher accuracy. The growth of the category is anticipated to be positively impacted by these qualities. From 2024 to 2030, the immunohistochemistry segment is anticipated to expand at the quickest CAGR. Because of its substantial uses in the detection of enzymes, antigens, tumor suppressor genes, and tumor cell proliferation for cell-based research, the market is expected to increase steadily. Additionally, immunohistochemistry's development possibilities have increased due to rising R&D expenditure and a high degree of scientific understanding surrounding the method.

Furthermore, some of the reasons expected to propel the market expansion are the advantages offered by the approach, such as its high sensitivity and ease of use. The immunohistochemistry category is anticipated to expand at the quickest rate between 2024 and 2030. Its important applications in the detection of enzymes, antigens, tumor suppressor genes, and tumor cell proliferation for cell-based research are expected to drive the segment's steady expansion. Furthermore, growing R&D expenditures and a high degree of scientific knowledge about the method have increased immunohistochemistry's development possibilities. The technique's advantages, such its high sensitivity and ease of use, are just some of the things that are expected to propel the market's expansion.

Because rabbits produce antibodies with greater affinity and specificity, they accounted for the greatest market share in 2023. Because of their high rate of reproduction and structural resemblance to human antibodies, the mouse source sector is anticipated to grow at the quickest pace between 2024 and 2030.

Because cancer is becoming more common, the oncology category dominated the market in 2023. Novel therapeutic and diagnostic strategies are being developed using antibodies. As more research is conducted and stem cells are used to treat chronic illnesses, the market is predicted to expand quickly. The creation of reprogramming procedures, drug screening, illness modeling, developmental biology, and cell therapy all make use of antibodies.

With the biggest revenue share in 2023, the academic & research institutions category is expected to increase at the quickest rate throughout the course of the forecast period. This can be linked to the rise in research efforts by these institutes to provide new treatments and diagnostic tools for long-term illnesses. Researchers at The University of Texas Medical Branch at Galveston (UTMB Health) and The University of Texas Health Science Center at Houston (UTHealth), for example, identified two new antibodies, CoV2-06 and CoV2-14, in January 2021 as part of a possible novel antibody treatment for COVID-19 infection. Such activities may have a favorable impact on the growth of the market in the near future. Due to the rise in R&D efforts in the life sciences sector, the end-use segment of pharmaceutical and biotechnology firms is anticipated to grow at a high CAGR during the forecast period. Additionally, the growing need for quality control applications for different procedures like PCR and electrophoresis, as well as the growing significance of antibodies for the creation of innovative biologic products, are anticipated to propel the segment's expansion.

Research Antibodies Market Players:

1. Abcam Plc

2. Becton, Dickinson and Company

3. Bio-Rad Laboratories, Inc.

4. Bio-Techne Corporation

5. Cell Signalling Technology, Inc.

6. Eli Lilly, and Company.

7. Jackson ImmunoResearch Inc.

8. Johnson & Johnson Services, Inc.

9. Merck KGaA

10. Novartis AG

11. PerkinElmer, Inc.

12. Proteintech Group, Inc.

13. Rockland Immunochemicals, Inc.

14. Santa Cruz Biotechnology Inc.

15. Thermo Fisher Scientific, Inc.

Recent Developments:

2 May 2023: Cellular Biomedicine Group Inc. and Janssen Biotech, Inc., one of Johnson & Johnson's Janssen Pharmaceutical Companies, have signed a global licensing and cooperation agreement.

24 April 2023: Johnson & Johnson Launched Kenvue Inc. IPO Roadshow.

Research Antibodies Market Trends

Due to the growing incidence of neurological diseases including Huntington's, Multiple Sclerosis, and Parkinson's, as well as R&D efforts for vaccines and treatments, research antibodies are in high demand. The need for research antibodies is also influenced by the aging population and the dearth of therapies for chronic illnesses. High-quality antibodies, proteomics and genomics research, life sciences research, industry-academia collaborations, stem cell research, and neurobiology research are the main factors propelling the market's expansion. Growth is being driven by outsourcing interests, biomarker development, and funding from nonprofit and for-profit organizations. Biotechnology companies like Thermo Fisher are expanding their value offering in response to the growing need for customized medicine and protein treatments.

Research Antibodies Market Regional Analysis

With the biggest revenue share of 39.15% in 2023, North America led the market. Its substantial market share is mostly due to the growing emphasis on biomedical, stem cell, and cancer research. The market is anticipated to increase due to the presence of major players like PerkinElmer, Inc. and Thermo Fisher Scientific, Inc. as well as the growing number of biotechnology and biopharmaceutical companies in the area that concentrate on life sciences innovation.

Because more academic institutions are working together, the Asia Pacific market is predicted to expand at the quickest compound annual growth rate (CAGR) between 2024 and 2030. In the present study, for example, researchers from Tsinghua University, China Medical University, and the NIH's Vaccine Research Center are examining the identification and characterization of HIV-1 strains and their strong and pervasive resistance to a range of neutralizing antibodies. This initiative was funded by the Gates Foundation Grand Challenges China, China's Ministry of Science and Technology, and the National Natural Science Foundation Award. Therefore, it is expected that the region's government-funded scientific endeavors would propel the market's expansion.

Key Market Segments: Research Antibodies Market

• Product Outlook (Revenue, USD Billion, 2024- 2033)

  • Primary Antibodies

  • Secondary Antibodies

• Type Outlook (Revenue, USD Billion, 2024- 2033)

  • Monoclonal Antibodies

  • Polyclonal Antibodies

• Technology Outlook (Revenue, USD Billion, 2024- 2033)

  • Immunohistochemistry

  • Immunofluorescence

  • Western Blotting

  • Flow Cytometry

  • Immunoprecipitation

  • ELISA

  • Others

• Source Outlook (Revenue, USD Billion, 2024- 2033)

  • Mouse

  • Rabbit

  • Goat

  • Others

• Application Outlook (Revenue, USD Billion, 2024- 2033)

  • Infectious Diseases

  • Immunology

  • Oncology

  • Stem Cells

  • Neurobiology

  • Others

• End Use Outlook (Revenue, USD Billion, 2024- 2033)

  • Academic & Research Institutes

  • Contract Research Organizations

  • Pharmaceutical & Biotechnology Companies

• Regional Outlook (Revenue, USD Billion, 2024- 2033)

  • North America

• Europe

• Asia Pacific

• Latin America

• Middle East & Africa